Last reviewed 2026-04-23 · How we verify

Xolair® + Symbicort®

Xolair (omalizumab) is an anti-IgE antibody that blocks the action of IgE, a protein involved in allergic reactions, while Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist that reduces inflammation and bronchospasm in the airways.

Xolair (omalizumab) is an anti-IgE antibody that blocks the action of IgE, a protein involved in allergic reactions, while Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist that reduces inflammation and bronchospasm in the airways. Used for Asthma maintenance and control, Chronic idiopathic urticaria.

At a glance

Mechanism of action

Omalizumab works by binding to IgE, preventing it from binding to its receptor on mast cells and basophils, which reduces the release of histamine and other mediators involved in allergic reactions. Budesonide is a corticosteroid that reduces inflammation in the airways, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes bronchial muscles and improves airflow.

Approved indications

• Asthma maintenance and control
• Chronic idiopathic urticaria

Common side effects

• Headache
• Nausea
• Cough
• Pharyngitis
• Sinusitis

Key clinical trials

• An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Xolair® + Symbicort® CI brief — competitive landscape report
• Xolair® + Symbicort® updates RSS · CI watch RSS
• AO GENERIUM portfolio CI